metoclopramide and co-beneldopa

Metoclopramide is a dopamine D2 receptor antagonist. Co-beneldopa provides levodopa, which is converted to dopamine centrally to restore dopaminergic tone in Parkinson's disease. By blocking central D2 receptors, metoclopramide directly antagonises the therapeutic effect of levodopa and can precipitate or worsen parkinsonian symptoms. Additionally, metoclopramide can cross the blood-brain barrier, leading to extrapyramidal adverse effects.

Concurrent use of metoclopramide with co-beneldopa is contraindicated because it can cause a marked worsening of Parkinson's disease symptoms, including increased tremor, rigidity, and bradykinesia. The patient may experience a loss of motor control and a decrease in the effectiveness of levodopa therapy. Extrapyramidal reactions such as acute dystonia, akathisia, and tardive dyskinesia may also occur, and these are more likely in patients with Parkinson's disease.

Do not prescribe metoclopramide to patients taking co-beneldopa. If antiemetic treatment is required, consider using an alternative antiemetic such as domperidone, which does not cross the blood-brain barrier and is less likely to worsen Parkinson's disease. Alternatively, other antiemetics such as cyclizine may be considered, but always consult current prescribing guidance and specialist advice. Monitor for any deterioration in motor function if an interaction is suspected.

This interaction is well documented in the summary of product characteristics for metoclopramide, which lists Parkinson's disease as a contraindication. Clinical guidelines and formularies consistently advise against concurrent use. The pharmacological rationale is well established, and the interaction is widely recognised.